Loading...
•
Dec 31, 2024
Collegium Q4 2024 Earnings Report
Collegium Pharmaceutical, Inc. reported record fourth quarter and full-year 2024 financial results, driven by strong performance in its pain portfolio and the addition of Jornay PM.
Key Takeaways
Collegium Pharmaceutical, Inc. achieved record financial results in Q4 2024, with net revenue of $181.9 million and adjusted EBITDA of $107.7 million. The company also reported GAAP net income of $12.5 million and repurchased $60.0 million in shares during 2024.
Generated record quarterly net revenue of $181.9 million, a 22% increase year-over-year.
Achieved quarterly GAAP net income of $12.5 million and adjusted EBITDA of $107.7 million.
Jornay PM prescriptions grew 11% quarter-over-quarter, with net revenue of $29.3 million.
Ended 2024 with $162.8 million in cash, cash equivalents, and marketable securities, after repurchasing $60.0 million in shares.
Revenue by Segment
Forward Guidance
Collegium Pharmaceutical, Inc. reaffirms its full-year 2025 guidance for Product Revenues, Net, Adjusted Operating Expenses, and Adjusted EBITDA.
Positive Outlook
- Projected Product Revenues, Net between $735.0 million to $750.0 million for FY 2025.
- Projected Adjusted EBITDA between $435.0 million to $450.0 million for FY 2025.
- Expected Jornay PM net revenue to be in excess of $135 million in 2025.
- Commitment to creating long-term value for shareholders by executing on commercial priorities and strategically deploying capital.
- Focus on growing Jornay PM and maximizing the pain portfolio.
Challenges Ahead
- The company is unable to provide a reconciliation of its full-year 2025 guidance for adjusted EBITDA or adjusted operating expenses to GAAP measures due to unreasonable efforts exception.
- Uncertainty regarding the timing and amount of items like stock-based compensation expense, acquisition related expense, and litigation settlements.
- These items are outside the Company's control and cannot be reasonably predicted.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...